The Development of SARS-CoV-2 Vaccines Using Various Strategies
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "COVID-19 Vaccines and Vaccination".
Deadline for manuscript submissions: closed (20 April 2022) | Viewed by 2803
Special Issue Editor
Interests: influenza viruses; Ebola virus; SARS-CoV-2; zoonotic viruses; pathogenicity; virus–host interaction; vaccines; adjuvants
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
SARS-CoV-2, which emerged at the end of 2019, is still rampant around the world, causing enormous health and economic damage. The development of SARS-CoV-2 vaccines has proceeded at an unprecedented pace, and several vaccines have already been approved and administered in many countries. However, despite expectations that global vaccination will lead to the end of the pandemic, variants possessing amino acid substitutions in the antigenic sites of the SARS-CoV-2 spike protein continue to emerge all over the world, raising concerns about the effectiveness of the current vaccines. Therefore, it is important to continue to develop vaccines using strategies that improve our preparedness for these emerging variants. In this Special Issue, we seek articles (both reviews and original research) discussing the development of SARS-CoV-2 vaccines using various strategies.
Dr. Tokiko Watanabe
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- SARS-CoV-2
- vaccines
- animal models
- variants
- vaccine platforms
